We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+42.24%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$2.31B
AUM Growth
+$640M
Cap. Flow
+$115M
Cap. Flow %
4.97%
Top 10 Hldgs %
73.01%
Holding
40
New
6
Increased
6
Reduced
12
Closed
8

Top Buys

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$46.1M
2
AMRN
Amarin Corp
AMRN
+$43.7M
3
ARRY
Array Biopharma Inc
ARRY
+$41.6M
4
MDCO
Medicines Co
MDCO
+$36.8M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$30.9M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$63.6M
2
LOXO
Loxo Oncology, Inc
LOXO
+$45.5M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$22.2M
4
TGTX icon
TG Therapeutics
TGTX
+$19.5M
5
ASND icon
Ascendis Pharma A/S
ASND
+$16.2M

Sector Composition

Rank Sector Weight
1 Healthcare 83.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
26
DELISTED
Cymabay Therapeutics
CBAY
$9.63M 0.42%
+725,000
New +$7.71M
ALIM
27
DELISTED
Alimera Sciences
ALIM
$6.61M 0.29%
416,000
– –
TLGT
28
DELISTED
Teligent, Inc
TLGT
$6.07M 0.26%
523,121
-6,879
-1% -$104K
FENC icon
29
Fennec Pharmaceuticals
FENC
$333M
$5.36M 0.23%
1,105,999
– –
KOD icon
30
Kodiak Sciences
KOD
$2.49B
$4.09M 0.18%
627,021
-275,179
-31% -$2.03M
XBI icon
31
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$1.27M 0.05%
+1,000,000
New +$85.1M
OTLK icon
32
Outlook Therapeutics
OTLK
$171M
$630K 0.03%
4,250
– –
NBIX icon
33
CALL
Neurocrine Biosciences
NBIX
$16.9B
– –
-50,000
Closed -$15K
PTCT icon
34
PTC Therapeutics
PTCT
$5.68B
– –
-380,000
Closed -$13M
TGTX icon
35
TG Therapeutics
TGTX
$7.07B
– –
-4,750,000
Closed -$19.5M
XBI icon
36
CALL
State Street SPDR S&P Biotech ETF
XBI
$9.62B
– –
-500,000
Closed -$1.44M
YMAB
37
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-310,000
Closed -$6.3M
KA
38
DELISTED
Kineta, Inc. Common Stock
KA
– –
-9,286
Closed -$4.21M
ACER
39
DELISTED
Acer Therapeutics Inc
ACER
– –
-150,000
Closed -$3.02M
LOXO
40
DELISTED
Loxo Oncology, Inc
LOXO
– –
-325,000
Closed -$45.5M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q1 2019 Portfolio in Review

As of Q1 2019, Avoro Capital Advisors held 40 positions worth $2.31B, up 38% from $1.67B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Avoro Capital Advisors deployed $115M of net new capital in Q1 2019, opening 6 new positions and adding to 6 existing holdings. Its largest new stake was MyoKardia, Inc. Common Stock: 1,000,000 shares worth $52M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 85% a quarter earlier.

On the sell side, the largest reduction was Mirati Therapeutics, Inc. Common Stock, an estimated $63.6M trimmed.

  • Avoro Capital Advisors's largest Q1 2019 buy was MyoKardia, Inc. Common Stock: 1,000,000 shares worth $52M.
  • Avoro Capital Advisors added most to Amarin Corp in Q1 2019, an estimated $43.7M increase.
  • Avoro Capital Advisors's biggest Q1 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $63.6M.
  • Avoro Capital Advisors fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $45.5M.
  • Avoro Capital Advisors's ten largest holdings make up 73% of its $2.31B portfolio in Q1 2019.
  • Avoro Capital Advisors opened 6 new positions and closed 8 in Q1 2019.
  • Avoro Capital Advisors's portfolio value rose 38% quarter-over-quarter to $2.31B.

Based on Avoro Capital Advisors's 13F filing for Q1 2019, filed 15 May 2019.